Clinical data | |
---|---|
Trade names | Quinaglute, Quinidex |
Other names | (2-Ethenyl-4-azabicyclo[2.2.2]oct-5-yl)-(6-methoxyquinolin-4-yl)-methanol |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | By mouth, intramuscular injection, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 70–85% |
Metabolism | 50–90% (by liver) |
Elimination half-life | 6–8 hours |
Excretion | By the liver (20% as unchanged quinidine via urine) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.254 |
Chemical and physical data | |
Formula | C20H24N2O2 |
Molar mass | 324.424 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Quinidine is a class IA antiarrhythmic agent used to treat heart rhythm disturbances.[1] It is a diastereomer of antimalarial agent quinine,[2] originally derived from the bark of the cinchona tree. The drug causes increased action potential duration, as well as a prolonged QT interval. As of 2019, its IV formulation is no longer being manufactured for use in the United States.[3]